156 related articles for article (PubMed ID: 20861476)
21. Biosynthesis and half-life of MBX-2168-triphosphate in herpes virus-infected cells.
Sauer HE; Nguyen ML; Williams JD; Bowlin TL; Gentry BG
Antiviral Res; 2020 Mar; 175():104713. PubMed ID: 31968222
[TBL] [Abstract][Full Text] [Related]
22. Acyclovir is phosphorylated by the human cytomegalovirus UL97 protein.
Talarico CL; Burnette TC; Miller WH; Smith SL; Davis MG; Stanat SC; Ng TI; He Z; Coen DM; Roizman B; Biron KK
Antimicrob Agents Chemother; 1999 Aug; 43(8):1941-6. PubMed ID: 10428917
[TBL] [Abstract][Full Text] [Related]
23. Replication-competent, oncolytic herpes simplex virus type 1 mutants induce a bystander effect following ganciclovir treatment.
Luo C; Mori I; Goshima F; Ushijima Y; Nawa A; Kimura H; Nishiyama Y
J Gene Med; 2007 Oct; 9(10):875-83. PubMed ID: 17685493
[TBL] [Abstract][Full Text] [Related]
24. Ganciclovir ophthalmic gel 0.15%: safety and efficacy of a new treatment for herpes simplex keratitis.
Kaufman HE; Haw WH
Curr Eye Res; 2012 Jul; 37(7):654-60. PubMed ID: 22607463
[TBL] [Abstract][Full Text] [Related]
25. Effect of acyclovir combined with other antiherpetic agents on varicella zoster virus in vitro.
Biron KK; Elion GB
Am J Med; 1982 Jul; 73(1A):54-7. PubMed ID: 6285733
[TBL] [Abstract][Full Text] [Related]
26. Evaluation of ganciclovir-mediated enhancement of the antitumoral effect in oncolytic, multimutated herpes simplex virus type 1 (G207) therapy of brain tumors.
Todo T; Rabkin SD; Martuza RL
Cancer Gene Ther; 2000 Jun; 7(6):939-46. PubMed ID: 10880026
[TBL] [Abstract][Full Text] [Related]
27. Effectiveness of acycloguanosine and trifluorothymidine as inhibitors of cytomegalovirus infection in vitro.
Lang DJ; Cheung KS
Am J Med; 1982 Jul; 73(1A):49-53. PubMed ID: 6285732
[TBL] [Abstract][Full Text] [Related]
28. In vitro and in vivo activity of 1-O-hexadecylpropanediol-3-phospho-ganciclovir and 1-O-hexadecylpropanediol-3-phospho-penciclovir in cytomegalovirus and herpes simplex virus infections.
Hostetler KY; Rybak RJ; Beadle JR; Gardner MF; Aldern KA; Wright KN; Kern ER
Antivir Chem Chemother; 2001 Jan; 12(1):61-70. PubMed ID: 11437323
[TBL] [Abstract][Full Text] [Related]
29. Fluorosubstitution and 7-alkylation as prospective modifications of biologically active 6-aryl derivatives of tricyclic acyclovir and ganciclovir analogues.
Ostrowski T; Golankiewicz B; De Clercq E; Balzarini J
Bioorg Med Chem; 2005 Mar; 13(6):2089-96. PubMed ID: 15727862
[TBL] [Abstract][Full Text] [Related]
30. Synergistic effects of acyclovir and 3, 19-isopropylideneandrographolide on herpes simplex virus wild types and drug-resistant strains.
Priengprom T; Ekalaksananan T; Kongyingyoes B; Suebsasana S; Aromdee C; Pientong C
BMC Complement Altern Med; 2015 Mar; 15():56. PubMed ID: 25879785
[TBL] [Abstract][Full Text] [Related]
31. Modifications on the heterocyclic base of ganciclovir, penciclovir, acyclovir - syntheses and antiviral properties.
Chuchkov K; Chayrov R; Hinkov A; Todorov D; Shishkova K; Stankova IG
Nucleosides Nucleotides Nucleic Acids; 2020; 39(7):979-990. PubMed ID: 32312162
[TBL] [Abstract][Full Text] [Related]
32. Intravitreal toxicology and duration of efficacy of a novel antiviral lipid prodrug of ganciclovir in liposome formulation.
Cheng L; Hostetler KY; Chaidhawangul S; Gardner MF; Beadle JR; Keefe KS; Bergeron-Lynn G; Severson GM; Soules KA; Mueller AJ; Freeman WR
Invest Ophthalmol Vis Sci; 2000 May; 41(6):1523-32. PubMed ID: 10798672
[TBL] [Abstract][Full Text] [Related]
33. Inhibition of human cytomegalovirus by trifluorothymidine.
Spector SA; Tyndall M; Kelley E
Antimicrob Agents Chemother; 1983 Jan; 23(1):113-8. PubMed ID: 6299179
[TBL] [Abstract][Full Text] [Related]
34. Temozolomide enhances herpes simplex virus thymidine kinase/ganciclovir therapy of malignant glioma.
Rainov NG; Fels C; Droege JW; Schäfer C; Kramm CM; Chou TC
Cancer Gene Ther; 2001 Sep; 8(9):662-8. PubMed ID: 11593335
[TBL] [Abstract][Full Text] [Related]
35. The Epstein-Barr virus (EBV)-encoded protein kinase, EBV-PK, but not the thymidine kinase (EBV-TK), is required for ganciclovir and acyclovir inhibition of lytic viral production.
Meng Q; Hagemeier SR; Fingeroth JD; Gershburg E; Pagano JS; Kenney SC
J Virol; 2010 May; 84(9):4534-42. PubMed ID: 20181711
[TBL] [Abstract][Full Text] [Related]
36. Attachment and penetration of acyclovir-resistant herpes simplex virus are inhibited by Melissa officinalis extract.
Astani A; Navid MH; Schnitzler P
Phytother Res; 2014 Oct; 28(10):1547-52. PubMed ID: 24817544
[TBL] [Abstract][Full Text] [Related]
37. Antiviral activity of Viracea against acyclovir susceptible and acyclovir resistant strains of herpes simplex virus.
Thompson KD
Antiviral Res; 1998 Jul; 39(1):55-61. PubMed ID: 9754950
[TBL] [Abstract][Full Text] [Related]
38. The antiherpesvirus activity of H2G [(R)-9-[4-hydroxy-2-(hydroxymethyl)butyl]guanine] is markedly enhanced by the novel immunosuppressive agent mycophenolate mofetil.
Neyts J; Andrei G; De Clercq E
Antimicrob Agents Chemother; 1998 Dec; 42(12):3285-9. PubMed ID: 9835529
[TBL] [Abstract][Full Text] [Related]
39. Differential impact of various substitutions at codon 715 in region II of HSV-1 and HCMV DNA polymerases.
Zarrouk K; Zhu X; Goyette N; Piret J; Shi R; Boivin G
Antiviral Res; 2021 Apr; 188():105046. PubMed ID: 33588012
[TBL] [Abstract][Full Text] [Related]
40. Activity of penciclovir in antiviral assays against herpes simplex virus.
Bacon TH; Howard BA; Spender LC; Boyd MR
J Antimicrob Chemother; 1996 Feb; 37(2):303-13. PubMed ID: 8707740
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
